An FDA panel is expected to review Eli Lilly and Co.’s (LLY) investigational antibody therapy Donanemab on June 10, 2024.Donanemab that targets a modified form of deposited amyloid-ß peptide called N3pG is proposed for the treatment of early symptomatic Alzheimer's disease. Last January, the FDA had declined to grant accelerated approval to Donanemab for the treatment of early symptomatic Alzheimer's disease based on limited number of patients with 12-month drug exposure data in the accelerated approval submission. LLY closed Wednesday’s trading at $811.53, up 0.45%.